Accelerated Approval Process Is Not Without Risk: Placing Recent FDA Action in Context | Troutman Pepper
On February 23, the Food and Drug Administration (FDA) withdrew approval of Pepaxto (melphalan flufenamide), a drug that it had previously granted accelerated approval for treatment of...
Source: jdsupra.com
